Evidence map›Paper›PMID 38053462›Full record

Observational studyRMD open2023

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.

Adrian Ciurea, Andrea Götschi, René Bräm, Kristina Bürki, Pascale Exer, Michael Andor, Michael J Nissen, Burkhard Möller, Thomas Hügle, Andrea Rubbert-Roth and 4 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adrian CiureaDepartment of Rheumatology, Zurich University Hospital, University of Zurich, Zurich, Switzerland adrian.ciurea@usz.ch.ORCID 0000-0002-7870-7132
Andrea GötschiSwiss Clinical Quality Management Foundation, Zurich, Switzerland.
René BrämSwiss Ankylosing Spondylitis Association, Zurich, Switzerland.
Kristina BürkiDepartment of Rheumatology, Zurich University Hospital, University of Zurich, Zurich, Switzerland.
Pascale ExerGemeinschaftspraxis Rheuma-Basel, Basel, Switzerland.
Michael AndorRheumatologie im Zürcher Oberland, Uster, Switzerland.
Michael J NissenDepartment of Rheumatology, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0002-6326-1764
Burkhard MöllerDepartment of Rheumatology and Immunology, Inselspital, Bern, Switzerland.
Thomas HügleDepartment of Rheumatology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3276-9581
Andrea Rubbert-RothDepartment of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland.ORCID 0000-0002-9016-2833
Diego KyburzDepartment of Rheumatology, University Hospital Basel, Basel, Switzerland.
Oliver DistlerDepartment of Rheumatology, Zurich University Hospital, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310
Almut SchererSwiss Clinical Quality Management Foundation, Zurich, Switzerland.
Raphael MicheroliDepartment of Rheumatology, Zurich University Hospital, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-8918-7304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterise the population fulfilling the Assessment of SpondyloArthritis international Society (ASAS) consensus definition of early axial spondyloarthritis (axSpA) and to determine the effectiveness of a first tumour necrosis factor inhibitor (TNFi) in early versus established axSpA in a large observational registry.

methodsA total of 3064 patients with axSpA in the Swiss Clinical Quality Management registry with data on duration of axial symptoms were included (≤2 years=early axSpA, N=658; >2 years=established axSpA, N=2406). Drug retention was analysed in patients starting a first TNFi in early axSpA (N=250) versus established axSpA (N=874) with multiple-adjusted Cox proportional hazards models. Adjusted logistic regression analyses were used to determine the achievement of the ASAS criteria for 40% improvement (ASAS40) at 1 year.

resultsSex distribution, disease activity, impairments of function and health-related quality of life were comparable between patients with early and established axSpA. Patients with established disease were older, had more prevalent axial radiographical damage and had a higher impairment of mobility. A comparable TNFi retention was found in early versus established disease after adjustment for age, sex, human leucocyte antigen-B27 status, education, body mass index, smoking, elevated C reactive protein and sacroiliac inflammation on MRI (HR 1.05, 95% CI 0.78 to 1.42). The adjusted ASAS40 response was similar in the two groups (OR 1.09, 95% CI 0.67 to 1.78). Results were confirmed in the population fulfilling the ASAS classification criteria.

conclusionConsidering the recent ASAS definition of early axSpA, TNFi effectiveness seems comparable in early versus established disease.

Indexed as

Axial SpondyloarthritisTumor Necrosis Factor InhibitorsCohort StudiesConsensus Statements as TopicHumansQuality of LifeRegistriesTreatment OutcomeTumor Necrosis Factor InhibitorsEpidemiologySpondylitis, AnkylosingTumor Necrosis Factor Inhibitors

Identifiers

PMID38053462
PMCPMC10693870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.